| Drug Class | Generic/Trade Company Names | Indication | Approving Regulatory Agency |
| Antiaging Treatments | Clindamycin Foam 1% Aluma®Skin Renewal System with FACES™ Lumenis | Approved for the noninvasive treatment of fine lines and wrinkles. | US FDA |
| Antibacterial Agents | Meropenem for Injection MERREM® AstraZeneca | Approved for the noninvasive treatment of fine lines and wrinkles. | US FDA |
| Moxifloxacin HCl Avelox® Bayer HealthCare Schering-Plough | Approved for the treatment of complicated skin and skin structure infections in adults and children. | US FDA | |
| Tygacycline Tygacil® Wyeth | Approved for the treatment of complicated skin and skin structure infections in adults that are caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae. | US FDA EMEA | |
| Antifungal Agents | Ciclopirox Topical Suspension 0.77% Taro Pharmaceuticals | Abbreviated NDA approved for the treatment of fungal infections of the skin. It is the bioequivalent of Medicis Pharmaceutical’s Loprox® Topical Suspension 0.77%. | US FDA |
| Griseofulvin Oral Suspension USP Glades Pharmaceuticals | Approved for the treatment of tinea barbae, tinea capitis, tinea corporis, tinea pedis, and tinea unguium (onychomycosis). | US FDA | |
| Terbinafine HCl Lamisil®Tablets Ranbaxy Laboratories | Approved for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). | US FDA | |
| Antihistamine | Desloratadine Syrup Clarinex®Reditabs® Schering-Plough | Reformulated 2.5mg and 5mg tablets approved for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and for chronic idiopathic urticaria, or hives of unknown cause, in adults and children >6 years of age. | US FDA |
| Antipruritic Agents | Epinastine HCl 1% Alesion®Dry Syrup Nippon Boehringer Ingelheim/ Sankyo | Approved for the treatment of allergic rhinitis, urticaria, and pruritus associated with skin diseases such as eczema and dermatitis in pediatric patients. | Japanese Ministry of Health, Labour and Welfare |
| Antipsoriatic Agents | Clobetasol Propionate 0.05% Clobex™Spray Galderma | For the treatment of moderate-to-severe plaque psoriasis. Clobex® is already available as a lotion and shampoo. | US FDA |
| Efalizumab Raptiva® Serono | Approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults >18 years of age who are candidates for systemic therapy or phototherapy. | TPD Canada | |
| Etanercept Enbrel® Amgen/ Wyeth Pharmaceuticals | Approved for the treatment of moderate-to-severe psoriasis in adults. | TPD Canada | |
| Fluocinonide 0.1% Vanos® Cream Medicis Pharmaceuticals | A new class I topical corticosteroid approved for the treatment of plaque-type psoriasis affecting up to 10% of the body surface area. | US FDA | |
| Infliximab Remicade® Centocor/ Schering-Plough | Approved for the treatment of moderate-to-severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapies including cyclosporine, methotrexate, or PUVA. | EMEA | |
| Atopic Dermatitis Agents | Fluticasone Propionate 0.05% Cutivate®Lotion Pharmaderm/Altana | Approved in patients >1 year of age for the treatment of atopic dermatitis. | US FDA |
| Hydrogel Dressing MimyX®Cream Stiefel Laboratories | A topical nonsteroidal cream approved for the treatment of atopic dermatitis. | US FDA | |
| HIV/AIDS | Emtricitabine Emtriva™Oral Solution Gilead Sciences | Approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients >3 months of age. | US FDA |
| Tipranavir Capsule Aptivus® Boehringer Ingelheim Pharmaceuticals | Accelerated approval for this nonpeptide protease inhibitor as a combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, and who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. The approved dose is 500mg taken with 200mg ritonavir twice daily | US FDA EMEA | |
| Leishmaniasis | Miltefosine Impavido™ AEterna Zantaris | Approved for the treatment of the cutaneous form of leishmaniasis as well as the visceral form of this condition. | Columbian Food and Drug Agency |
| Oncologic Agents | Imiquimod 5% Aldara™Cream 3M | Approved for the treatment of superficial basal cell carcinoma. | TPD Canada |
| Psoriatic Arthritis Agents | Adalimumab Humira™ Abbott Laboratories | Approved for the treatment of psoriatic arthritis. | US FDA |
| Etanercept Enbrel® Amgen/ Wyeth Pharmaceuticals | Approved for the improvement of physical function in patients with psoriatic arthritis. | US FDA | |
| Infliximab Remicade® Centocor/ Schering-Plough | Approved for the treatment of psoriatic arthritis. | US FDA | |
| Rosacea | Metronidazole Topical Gel 1% MetroGel® Galderma Laboratories LP | Approved for the topical treatment of inflammatory lesions of rosacea. | US FDA |
| Vaccines | Measles, Mumps, Rubella, and Varicella Virus Vaccine, Live ProQuad® Merck | Approved for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age. | US FDA EMEA |
| Wound Management | Antimicrobial Barrier Dressing ACTICOAT* Moisture Control Smith & Nephew | Approved for wound care as a barrier to bacterial penetration, featuring the patented Silcryst™ nanocrystalline silver technology. | US FDA |
